1Zlokovic BV.The blood-brain barrier in health and chronic neurodegenerative disorders.Neuron,2008,57(2):178-201.
2Boado RJ.Blood-brain barrier transport of non-viral gene and RNAi therapeutics.Pharm Res,2007,24(9):1772-1787.
3Boado RJ.A new generation of neurobiological drugs,engineered to overcome the challenges of brain drug delievery.Drug News Perspect,2008,21(9):489-503.
4Murugesan V,Parbhakar YS,Katti SB.CoMFA and CoMSIA studies on thiazolidin-4-ones as anti-HIV-agents.J Mol Graph Model,2009,27(6):735-743.
5Allen DD,Geldenhuys WJ.Molecular modeling of blood-brain harrier nutrient transporters:in silico basis for evaluation of potential drug delievery to the central nervous system.Life Sci,2006,78(10):1029-1033.
6Pavan B,Dalpiaz A,Ciliberti N,et al.Progress in drug delievery to the central nervous system by the prodrug approach.Molecules,2008,13(5):1035-65.
7Gynther M,Laine K,Ropponen J,et al.Large neutral amino acid transporter enables brain drug delievery via prodrugs.J Med Chem,2008,51 (4):932-936.
8Juillerat-Jeanneret L.The targeted delivery of cancer drugs across the blood-brain barrier,chemical modifications of drugs or drugnsnoparticles? Drug Discov Teday,2008,13(23-24):1099-106.
9Chen P,Bodor N,Wu WM,Prokai L.Strategies to target kyotorphin analogues to the brain.J Med Chem,1998,41(20):3773-81.
10Ohtsuki S.New aspects of the blood-brain barrier transporters:its physiological roles in the central nervous system.Biol Pharm Bull,2004,27(10):1489-96.
